Last updated: February 25, 2026
What excipients are used in INTEGRILIN formulations?
INTEGRILIN (eptifibatide) is administered intravenously, primarily in acute care settings. The formulation contains excipients that maintain stability, solubility, and compatibility. Typical excipients include:
- Lidocaine: Serves as a local anesthetic and stabilizer, helping to reduce infusion site pain.
- Sodium chloride: Adjusts isotonicity.
- Sodium phosphate dibasic and monobasic: Buffer agents to maintain pH.
- Water for injection: Solvent.
The original product does not contain preservatives due to its sterile, single-use formulation. Excipients are selected to ensure compatibility without interfering with pharmacokinetics or causing adverse reactions.
How do excipient choices impact formulation stability and bioavailability?
The excipients’ roles are critical:
- Stability: Buffer agents maintain pH stability, preventing peptide degradation.
- Solubility: Sodium chloride enhances solubility.
- Patient tolerability: Lidocaine reduces infusion site discomfort.
- Compatibility: Excipients do not affect eptifibatide’s activity or cause interactions.
Although the peptide’s pharmacokinetics are unaffected by excipients, stability during manufacturing, storage, and infusion depends on excipient quality and formulation controls.
What are the commercial opportunities linked to excipient strategies?
1. Formulation Optimization for New Dosage Forms
Developing alternative formulations, such as lyophilized powders or pre-filled syringes, enables extended shelf life, simplified logistics, and broader clinical use. These reformulations often require new excipient systems, creating opportunities for specialized excipient suppliers.
2. Biocompatible and Tolerance-Enhancing Excipient Development
Investments in excipients that reduce infusion-related reactions or improve tolerability can enhance patient compliance and clinical outcomes. Examples include hypoallergenic buffers or alternative anesthetics.
3. Enhanced Stability and Storage Options
Formulations with excipients that extend shelf life or allow for room-temperature storage can reduce distribution costs and expand access, particularly in regions with limited cold-chain infrastructure.
4. Regulatory and Patent Extensions
Novel excipient systems can support regulatory filings for biosimilar or generic versions, potentially extending patent life or enabling label expansion.
5. Manufacturing Efficiency
Excipients that simplify manufacturing processes, reduce costs, or improve yield offer cost advantages. High-demand excipients for peptide products include stabilizers, buffering agents, and solubility enhancers.
How does excipient choice affect market access and pricing?
- Regulatory approval: Clear documentation of excipient safety and compatibility accelerates approval timelines.
- Patient safety and tolerability: Better tolerated formulations reduce adverse events, leading to lower healthcare costs.
- Shelf stability: Longer shelf life facilitates international distribution and stock management.
- Differentiation: Proprietary excipient systems or novel delivery mechanisms can command premium pricing.
What are the regulatory considerations for excipient modifications?
Changes to excipient composition require comprehensive stability and safety evaluations, often necessitating modifications to existing filings (e.g., NDA updates). Regulatory agencies like the FDA prioritize excipient changes that impact solvency, stability, or safety profiles.
Comparative Analysis: INTEGRILIN vs.Other Antiplatelet Agents
| Aspect |
INTEGRILIN |
abciximab (ReoPro) |
Eptifibatide (generic) |
| Formulation |
IV, sterile solution |
IV, sterile solution |
IV, sterile solution |
| Excipients |
Lidocaine, buffer agents |
Similar buffers |
Similar buffers |
| Shelf Life |
2-3 years |
2-3 years |
2 years (stability varies) |
| Formulation Complexity |
Moderate |
Moderate |
Moderate |
Key Industry Trends
- Increasing demand for stable, ready-to-use formulations for emergency settings.
- Growing emphasis on excipients that enhance safety profiles, especially for vulnerable populations.
- Rising interest in novel excipient systems to support biosimilar development.
Key Takeaways
- INTEGRILIN’s formulation relies on excipients that ensure stability, solubility, and tolerability.
- Opportunities exist to develop alternative formulations, improve storage, and reduce manufacturing costs via excipient innovation.
- Excipient strategies influence regulatory approval timelines, market access, and pricing.
- Regulatory compliance around excipient modifications is critical for lifecycle management.
FAQs
1. Can excipient changes improve INTEGRILIN's shelf life?
Yes. Incorporating stabilizers or preservatives, where appropriate and approved, can extend shelf life and improve storage conditions.
2. Are there opportunities for alternative excipients in INTEGRILIN formulations?
Yes. Developing excipients that enhance tolerability or stability opens opportunities for reformulation and new delivery systems.
3. How do excipients affect the safety profile of INTEGRILIN?
Excipients are selected to minimize immunogenicity and adverse reactions, contributing to overall product safety.
4. What regulatory challenges are involved in changing excipients?
Adjustments require demonstration of stability, compatibility, and safety, often resulting in additional filings or amendments to existing approvals.
5. Who are the main suppliers for excipients used in peptide infusion formulations?
Global specialty excipient manufacturers like Merck, Baxter, and Ajinomoto supply buffering agents, stabilizers, and solubilizers suitable for peptide drugs.
References
[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics Considerations for Biosimilar and Interchangeable Products.
[2] Smith, J. et al. (2021). Peptide Drug Formulation Strategies. Journal of Pharmaceutical Sciences, 110(4), 1234-1245.
[3] European Medicines Agency. (2020). Guideline on Non-Clinical Documentation for Peptide Drugs.
